Trial reportBMC cancer2026
ZR2-miniCHOP for elderly patients with newly diagnosed diffuse large B-cell lymphoma.
Trial report in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundVery old or frail patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) frequently cannot tolerate full-dose R-CHOP, and long-term control with R-miniCHOP is suboptimal. We assessed a sequential, chemotherapy-limiting regimen using zanubrutinib, lenalidomide, and rituximab (ZR2) induction followed by response-adapted ZR2-miniCHOP.
methodsThis single-center, open-label, investigator-initiated phase 2 trial enrolled untreated patients aged ≥ 80 years, or 60–79 years with ECOG performance status ≥ 2. All patients received two 21-day cycles of chemotherapy-free ZR2 (zanubrutinib 160 mg twice daily continuously; lenalidomide 25 mg once daily on days 1–10; rituximab 375 mg/m2 on day 0), then four cycles of ZR2 plus reduced-dose miniCHOP. PET/CT after cycle 6 determined consolidation: two cycles of ZR2 maintenance for complete responders or two additional cycles of ZR2-miniCHOP for partial responders. Primary endpoints were overall response rate (ORR) and complete remission (CR) rate after six cycles; secondary endpoints included progression-free survival (PFS), overall survival (OS), and safety.
resultsForty-eight patients were treated (median age 78 years; 45.8% ≥ 80; 70.8% high-risk by R-IPI). After ZR2 induction, ORR was 100% with 33.3% CR. By the end of treatment, ORR remained 100% and CR increased to 80.5%. At a median follow-up of 28.7 months, 2-year PFS and OS were 76.1% and 81.4%, respectively, with no CNS relapses observed. Grade 3–4 toxicities were mainly hematologic (neutropenia 29.2% during induction; 34.8% with miniCHOP), and no treatment-related deaths occurred.
conclusionsSequential ZR2 induction followed by response-adapted ZR2-miniCHOP achieved rapid, deep, and durable remissions with manageable toxicity in elderly or frail DLBCL, warrants further evaluation in randomized trials.
trial registrationChinese Clinical Trial Registry (ChiCTR2100047738), registered on 25 June 2021.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.